Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. - Wikidata - wikimedia - TriplyDB

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

http://www.wikidata.org/entity/Q33369267

about

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.Pemetrexed for the treatment of non-small-cell lung cancer.Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.Treatment of advanced non small cell lung cancer.Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis.Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines Epothilones in the treatment of cancer.Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma.Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer.Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis.The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients.Docetaxel in the treatment of advanced non-small-cell lung cancer.New avenues for second-line treatment of metastatic non-small-cell lung cancer.A Novel Metabolite from Aspergillus ochraceus JGI 25 Showing Cytotoxicity to Hela Cells.A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer.Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.Refining the treatment of advanced nonsmall cell lung cancer.Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Effect of chemotherapy on quality of life in patients with non-small cell lung cancer.Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Metabolism of the taxanes including nab-paclitaxel.

P2860

Q30317149-A7E15A6A-2997-427A-8E9D-96810883FA72 Q33301768-7AB540A9-2EDC-4B28-B978-99BF7AF507BA Q33303614-A8F6AB17-13B2-4AE7-B2A9-A56810EDBED2 Q33378383-79F1DE80-7191-4D3D-BEC1-1499C7AD1DEA Q33378865-0D878C19-3066-4643-A926-337C0A670123 Q33390208-6265E552-608F-425D-91FC-F3151661C9DE Q33795052-7A35B13A-F340-4E3B-85B7-C7527F3F473E Q34159161-1DC805FF-7D34-42FB-AE16-8722A2121E3D Q34344182-F9E4BD0C-A379-4AC4-9070-954AD409ABFB Q34623415-90EE7D8F-47F8-40AC-8FE9-3B9E06825713 Q35003631-1DF86F48-5C34-4EB7-97D0-41EB4BEDFB92 Q35375610-B5E0288F-26BE-4C7D-9383-618E57A4E341 Q35667817-1EF7B160-AC97-4CD4-8BD5-FD7811CBD48E Q35674153-8AAFE1FA-2A99-4F31-98A4-B22496DDBA90 Q35877763-792EE695-7207-4289-8AE4-831FBFBFC2EC Q36040002-D7DD9FC6-E242-42A1-BAA1-89C5B8433F6A Q36070770-F3BE52B3-2990-49F4-897E-FC93FCF57809 Q36142491-1179292A-2514-40C7-9F9F-E1E26F0E0392 Q36412597-3D8F7185-58F0-470E-8A99-6D1E636DA493 Q36491842-646C4D9D-A5A8-49C1-B515-37BD0CBAD236 Q36609433-79C3CC1C-2D45-4914-8A3E-B55DBCAD9469 Q36615597-14E9F439-668B-4580-A657-67E36FA45015 Q36636822-F6F547D7-1599-4E63-9DD2-F997822415D7 Q37030260-C864C321-83BB-4FAF-A93B-D76871087C9D Q37108127-48A53F7C-EF54-48A5-BD1F-36FDDBBE8193 Q37135295-EC1BD311-6C1E-4274-8775-4EA463A1ACA9 Q37185876-08B719C9-5C82-46CD-9E0D-B5154E2D39E2 Q37205484-5A77E4AC-D055-46C7-BAE0-123C93A65F3B Q37242661-46C97975-0F48-4BB6-A408-F6A14400BFE9 Q37357304-C0382737-AC62-43A0-AE95-F3C63AE6E5C6 Q37423977-F023DB25-E5B6-4F7D-BB2F-CADEFCB94EF6 Q37620539-A8974433-826C-485A-B832-171C73B5B86B Q37634957-0834EC16-7208-49AC-8403-A0C9656E672F Q37645169-49B265BE-E5E5-4A2D-A0DD-D6F0F0301688 Q37732287-49FDB5B5-9527-4EFB-B5B6-B9A993B8D86D Q37945643-D6AF08E9-95F3-4B66-A11E-D940EC8BE051 Q37957744-EC8858A5-D6DE-4F1A-9850-780F66775FD5 Q38190461-C23391BC-93E1-4DCD-8A29-E8CDB6DDB48C Q38258744-F5CE705D-1E36-4471-8B76-7ECA6A29CDF5 Q38267987-552C6A74-D810-4EE7-A106-366CA17B674A

P2860

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

http://www.wikidata.org/entity/Q33369267

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@ast

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@en

type

label

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@ast

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@en

prefLabel

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@ast

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@en

P1433

Q33369267-D813021D-388C-4D3B-A6B1-35A35D14F918

P1476

Q33369267-B57640DC-D909-4C7C-956D-8E4F64440F0A

P2093

Q33369267-320A7338-0E51-422D-A065-DAE1E6EE44BF

Q33369267-3573C417-3646-4B7D-B103-57D17ED1CCA1

Q33369267-3CFF3639-093D-4831-B2A6-8DA9C38D0D22

Q33369267-464667AD-DFEF-415B-9EBD-624D1F115E1B

Q33369267-50BEFE08-8CBC-460D-9254-6491C8F5F5F4

Q33369267-71479BFF-6583-4E5F-8784-98549EB910A2

Q33369267-AAE53949-2D84-44D6-965A-4D33CF0F7AAC

Q33369267-B8B5990D-1D08-4E0A-A0CA-312A13705303

Q33369267-BCF6B0B2-89A4-4F7E-930D-8A8A7CEBA68E

Q33369267-C47ABF47-DA57-453B-B227-15122DCB486D

P304

Q33369267-7A96607C-9D8B-43C8-A4E7-A886E969DDD5

P31

Q33369267-9AB2326C-400D-4A0A-A451-354FA7DE3E1E

P356

Q33369267-BB5D984E-3E2E-4E37-8E94-19BB29A9E40A

P407

Q33369267-ABCF0BE2-1DC0-4138-B94C-51ABB6581A0E

P433

Q33369267-35E2558F-9046-40A0-9704-F25F2E90A38A

P478

Q33369267-E916B119-9005-4B7C-AB04-04E9CA8866DF

P50

Q33369267-021B08D6-41D9-46A7-B506-F9FA05DCC33F

Q33369267-7087BC88-4A87-4A3E-A02E-23E516A5A0A6

P577

Q33369267-E06DD021-8909-4E6C-8BB4-F5A7AE55942F

P5875

Q33369267-41F52207-F0FB-4234-93A6-6D167609DC15

P698

Q33369267-C3B8756A-27D0-45DD-8971-AE7D73E0019E

P921

Q33369267-2F5E024F-60CF-4A78-9CFC-B4E246D74C4D

P356

JCO.2005.02.3739

P1433

Journal of Clinical Oncology

P1476

Phase III study of second-line ...... pared with 3-weekly docetaxel.

@en

P2093

Angelika Reissig

http://www.w3.org/2001/XMLSchema#string

Aruna Raghavachar

http://www.w3.org/2001/XMLSchema#string

Christine Lautenschlaeger

http://www.w3.org/2001/XMLSchema#string

Ernst-Wilhelm Schmidt

http://www.w3.org/2001/XMLSchema#string

Hans Schweisfurth

http://www.w3.org/2001/XMLSchema#string

Ina Dittrich

http://www.w3.org/2001/XMLSchema#string

Klaus Hans

http://www.w3.org/2001/XMLSchema#string

Ludwig Fischer von Weikersthal

http://www.w3.org/2001/XMLSchema#string

Monika Serke

http://www.w3.org/2001/XMLSchema#string

Sylke Nagel

http://www.w3.org/2001/XMLSchema#string

P304

8389-8395

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.3739

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Ludwig Fischer von Weikersthal

Wolfgang Schuette

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7474517

http://www.w3.org/2001/XMLSchema#string

P698

16293869

http://www.w3.org/2001/XMLSchema#string

P921